Acepodia dosed the first patient in a Phase I trial of ACE723, a GPC3-targeted dual-payload ADC for liver cancer. Read the ...
Step Pharma shares early Phase II VECTRA trial data for dencatistat in essential thrombocythaemia (ET) ahead of ASH 2026.
Mondego Bio has begun first-in-human dosing of MB-388, an oral PTPN2/PTPN1 inhibitor aimed at overcoming cancer immunotherapy ...
Moderna's mRNA-2808 yields four confirmed responses in Phase I/II myeloma study targeting BCMA, GPRC5D and FcRH5. Read the ...
Alethio Therapeutics raises USD 90M Series A to advance ATX-011, a G6B antibody for essential thrombocythaemia. Read the ...
Cambridge spinout T-Therapeutics closes $133m Series B to advance TCR bispecifics in cancer and autoimmune disease. Read the full story for what's next.
Cardiol Therapeutics unveils a USD 75M at-the-market equity program after its MAVERIC Phase III trial met enrollment early.
Emvena Therapeutics launches with seed funding from the Penn-BioNTech PxB Fund to build placenta-targeted mRNA medicines.
Novo Nordisk Q3'26 earnings: Neuropathic pain expansion and next-generation obesity pipeline advance
Novo Nordisk Q3 2026 earnings show CagriSema outperforming tirzepatide in weight loss. Explore the full pipeline update, ...
AbbVie licenses Nxera's oral EP4 agonist NXE0033744 for IBD in a $100M upfront global deal. Read the key terms and what this ...
AstraZeneca withdraws its EU application for Truqap in PTEN-deficient prostate cancer after a CHMP provisional opinion. Read ...
A2 Biotherapeutics' MSLN-targeting A2B694 CAR T therapy produced a 12-month-plus complete response in one NSCLC patient. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results